How Louisiana’s New Surgeon General Wants To Transform Public Health
Rosemary Westwood, The New York Times / kffhealthnews - Evelyn Griffin is pushing for more emphasis on wellness and prevention. She has also aligned with the MAHA movement in fighting government mandates and questioning the safety of some vaccines.
AI Summary: Louisiana’s new surgeon general outlined an ambitious agenda to revamp public health, prioritizing prevention, health equity and system reforms to tackle chronic disease and access gaps. The plan emphasizes community engagement, measurable targets and pragmatic policy levers—basically, less brochure writing and more fixing the plumbing of a beleaguered health system.
Charles Roberts Named the Next President and CEO of St. Jude Children’s Research Hospital
oncodaily - Charles Roberts, Current Cancer Center Director and Executive Vice-President and Next President and CEO of St. Jude Children’s Research Hospital, shared St. Jude Children’s Research Hospital’s post on LinkedIn, adding: […]
AI Summary: Charles Roberts was named president and CEO of St. Jude Children’s Research Hospital, stepping into leadership of a globally recognized pediatric cancer and research institution. He’ll oversee strategy, fundraising and clinical priorities as the center pursues ambitious research and care goals — and deal with the inevitable complexity of running a world-class nonprofit hospital.
AI may know how you’ll respond to a vaccine before you get it
sciencedaily - AI may be able to predict how strongly someone will respond to a vaccine before they receive it. By analyzing antibody patterns in more than 4,000 people, researchers found signs of “immune readiness” that helped distinguish strong responders from weak on…
AI Summary: Researchers report AI models that can forecast individual immune responses to vaccines by identifying predictive biological signatures. These tools could enable personalized vaccination strategies and smarter trial design, although real‑world validation and ethical deployment remain necessary before clinics trade one‑size‑fits‑all jabs for algorithmic matchmaking.
FDA Lists More Than 1,500 AI-Enabled Medical Devices as Oncology Applications Expand
oncodaily - The U.S. Food and Drug Administration (FDA) has listed more than 1,500 artificial intelligence-enabled medical devices authorized for marketing in the United States, reflecting the growing integration of AI across […]
AI Summary: The FDA catalogued more than 1,500 AI‑enabled medical devices, spurring criticism that most were cleared without direct evidence they improve patient outcomes. Regulators and clinicians face mounting calls for post‑market studies and transparency, balancing enthusiasm for AI innovation against the sober question: do these devices actually help patients?
Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease
Frank Vinluan / medcitynews - Ultragenyx Pharmaceutical’s Genglycos received accelerated FDA approval for glycogen storage disease type Ia, an inherited enzyme deficiency. It’s also the first approved gene therapy for Ultragenyx, which specializes in rare disease treatments. The post …
AI Summary: Ultragenyx received FDA approval for a gene therapy, marking the first approved treatment for that particular ultra‑rare disorder. The decision provides a regulated therapeutic option for patients previously without approved care, highlighting the evolving regulatory willingness to greenlight transformative but small‑population medicines.
ENZAMET: Enzalutamide Maintains Long-Term Survival Benefit in mHSPC
oncodaily - Treatment intensification with androgen receptor pathway inhibitors has become central to the management of metastatic hormone-sensitive prostate cancer (mHSPC). However, as patients remain on these therapies for years, longer follow-up […]
AI Summary: Long-term follow-up from ENZAMET shows enzalutamide continues to deliver a substantial overall survival benefit at eight years for patients with metastatic hormone-sensitive prostate cancer. The durable outcome cements enzalutamide’s role in combination androgen-deprivation strategies, giving patients and clinicians a proven option — not a cure, but progress that actually lasts.
R1 drills down on AI prior authorizations with Humata buy
Jill Hughes / healthcaredive - The revenue cycle company wants to automate claims processing, and RI is banking that Humata’s track record of streamlining medical preapprovals should help further that goal.
AI Summary: R1 has moved to buy Humata Health, folding AI-driven prior authorization tools into its revenue-cycle stack. The acquisition targets faster, more automated approval workflows for payers and providers, promising efficiency gains — and the usual question: will automation fix paperwork or just rebrand it as “innovation”?
Cityblock inks deal to acquire Homeward Health to move into rural healthcare, lands $116M funding round
fiercehealthcare - Combined, the two companies will serve nearly 250,000 people and are positioned to reach the120 million people receiving government-funded healthcare in the U.S., Toyin Ajayi, Cityblock Health CEO and co-founder wrote in a blog post.
AI Summary: Cityblock Health has acquired Homeward Health, signaling a strategic push into rural Medicare services backed by fresh funding. The deal aims to blend Cityblock’s value-based, whole-person care model with Homeward’s rural footprint, promising expanded access — and yes, more venture-capital-fueled disruption in places that actually need care.